# contextual query Ambiguous (TAMs)

Query: The following is a list of genes enriched in tumour microenvironment cells from a (human) patient with glioblastoma  annotated as Myeloid.  What might this list say about the state, properties and interactions of this cell type?  Do not limit your answers to the cancer literature,  include normal cell-cell interactions, development and cross-cutting metabolic states.  Gene list: ['LRMDA', 'LNCAROD', 'APBB1IP', 'DLEU1', 'FYB1', 'ARHGAP24', 'TBXAS1', 'DOCK8', 'ST6GAL1', 'SLCO2B1']

The gene list you provided, enriched in **myeloid cells** within the glioblastoma (GBM) tumor microenvironment, highlights a multifaceted cell state shaped by immunological, developmental, and metabolic adaptations. Here’s what these genes suggest about the properties, state, and interactions of these myeloid cells, in both cancer and normal contexts:

### 1. Immune Regulation and Cell–Cell Interactions

**APBB1IP (RIAM) and FYB1 (ADAP)**  
- Both play crucial roles in **integrin signaling, immune synapse formation, and cell migration**. APBB1IP interacts with Rap1 to activate integrin-mediated adhesion, essential for leukocyte trafficking, while FYB1 is involved in T-cell activation and signal transduction.
- In normal physiology, they facilitate immune surveillance and response; in the TME, they might support tumor-associated macrophage (TAM) migration, immune evasion, or contribute to immunosuppressive niches.

**DOCK8**  
- Functions as a **guanine nucleotide exchange factor** involved in actin cytoskeleton regulation, necessary for **immune cell movement, synapse formation, and antigen presentation**.
- Deficiency in DOCK8 impairs myeloid and lymphoid cross-talk, increasing susceptibility to infections and possibly dampening anti-tumor responses.

**ARHGAP24**  
- Negative regulator of Rho GTPases, it influences **phagocytosis, cell migration, and cytoskeletal remodeling**. In the TME, this could affect how myeloid cells infiltrate, survey, and respond to tumor cells or signals.

### 2. Transcriptional and Developmental Regulation

**LRMDA and TBXAS1**  
- **LRMDA**: Involved in melanocyte development but also expressed in hematopoietic and immune cells, implying a role in **cell lineage differentiation or identity** within the myeloid compartment.
- **TBXAS1 (Thromboxane synthase 1)**: Enzyme in the **eicosanoid pathway** generating thromboxane A2, which regulates platelet aggregation and vascular tone. In myeloid cells, this may be linked to **pro-inflammatory signaling or tissue remodeling**—processes that are co-opted in tumor angiogenesis and immune modulation.

### 3. Metabolic Adaptation

**SLCO2B1 and ST6GAL1**  
- **SLCO2B1** encodes an organic anion transporter involved in **prostaglandin and steroid transport**, reflecting adaptation to the metabolic demands and signaling milieu of the tumor.
- **ST6GAL1** encodes a sialyltransferase that **modifies cell surface glycoproteins**, affecting interactions with other immune cells and potentially modulating immune recognition (e.g., by masking antigens or altering adhesion).

### 4. Non-coding RNA and Regulatory Functions

**LNCAROD and DLEU1**  
- Both are **long non-coding RNAs** (lncRNAs) with roles in **transcriptional and post-transcriptional gene regulation**.
- LNCAROD has been implicated in immune regulation and cell differentiation, while DLEU1 is linked to cell cycle and survival pathways in both immune and tumor cells.
- Their expression suggests active **epigenetic and transcriptional modulation**, potentially reinforcing immunosuppressive or pro-tumoral phenotypes in the myeloid compartment.

### 5. Functional Properties and Crosstalk

Collectively, this gene signature supports a **state of activation, migration, and metabolic adaptation** characteristic of tumor-associated myeloid populations such as **macrophages**, **monocytes**, and **myeloid-derived suppressor cells (MDSCs)**. These cells are known to:
- Contribute to **immunosuppression** (e.g., via secretion of cytokines, metabolic competition, or immune checkpoint expression)[1][4].
- Participate in **angiogenesis** and **extracellular matrix remodeling**[3].
- Engage in **metabolic crosstalk** with tumor cells, adapting to hypoxic and nutrient-limited conditions by altering energy metabolism (e.g., via lipid transport, eicosanoid synthesis, or glycosylation patterning)[4].
- Mediate both **pro- and anti-inflammatory signaling**, switching phenotypes in response to environmental cues.

### Summary Table of Gene Functions and Implications

| Gene        | Normal Myeloid Function              | Tumor Microenvironment Implications                                | Broad Cellular/Metabolic Themes              |
|-------------|--------------------------------------|--------------------------------------------------------------------|----------------------------------------------|
| APBB1IP, FYB1 | Migration, activation, adhesion      | Immune infiltration, immune synapse, immunosuppression             | Cell signaling, motility                     |
| DOCK8, ARHGAP24 | Cytoskeletal dynamics, phagocytosis | Antigen presentation, migration, immunosurveillance                | Cytoskeleton, interaction with tumor         |
| TBXAS1, SLCO2B1 | Lipid/prostaglandin metabolism      | Angiogenesis, inflammation, metabolic adaptation                    | Eicosanoid signaling, metabolic competition  |
| ST6GAL1        | Glycosylation, cell-cell contact    | Immune evasion, altered recognition, tumor progression              | Glycobiology, cell adhesion                  |
| LNCAROD, DLEU1 | Gene regulation, cell identity      | Epigenetic adaptation, immune phenotype modulation                  | Transcriptional network, plasticity          |
| LRMDA          | Lineage specification               | Differentiation, immune cell composition                            | Developmental fate, cell type identity       |

This gene set thus signals **a highly adaptive, metabolically flexible, and immunomodulatory myeloid state**, shaped by and contributing to the complex, suppressive, and pro-tumoral environment of glioblastoma—yet many elements are conserved from normal myeloid differentiation, migration, and immune interaction in healthy tissue and development[1][3][4].



## References

- [1] IMMU-25. ANALYSIS OF IMMUNOSUPPRESSIVE MYELOID CELLS IN THE GLIOBLASTOMA TUMOR MICROENVIRONMENT REVEALS THERAPEUTICALLY TARGETABLE IMMUNOMODULATORY SIGNALS ACROSS POPULATIONS https://academic.oup.com/neuro-oncology/article/25/Supplement_5/v147/7406141 2023-11-01 None
- [2] OS07.1.A INTEGRATIVE SINGLE NUCLEI, SPATIAL, AND FUNCTIONAL GENOMIC ANALYSES REVEAL DNA-PK DRIVES GLIOBLASTOMA RADIORESISTANCE THROUGH TUMOR CELLS AND THE MYELOID MICROENVIRONMENT https://academic.oup.com/neuro-oncology/article/26/Supplement_5/v22/7825124 2024-10-01 None
- [3] Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches https://www.frontiersin.org/articles/10.3389/fphar.2024.1355242/full 2024-03-08 None
- [4] Metabolic adaptation of myeloid cells in the glioblastoma microenvironment https://www.frontiersin.org/articles/10.3389/fimmu.2024.1431112/full 2024-12-23 None
- [5] TMIC-20. UNLOCKING THE POTENTIAL OF HYPOXIA REDUCTION IN RESHAPING THE GLIOBLASTOMA TUMOR MICROENVIRONMENT FOR ENHANCED THERAPEUTIC SYNERGY https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii301/7890215 2024-11-01 None